Troriluzole – Talk Bio

FDA Delays Decision on Biohaven’s Troriluzole for Rare Disease, Plans Advisory Committee Review

3 weeks ago talkbio0Tagged Advisory Committees, Ataxia, Spinocerebellar, Biohaven, Deferred, disease drug, Extension, Infrequent, Neurodegenerative Disorders, PDUFA, Troriluzole, United States Food and Drug Administration

Biohaven; FDA delay; troriluzole; spinocerebellar ataxia (SCA); rare disease drug; PDUFA extension; advisory committee; neurodegenerative disease

Biohaven Achieves Breakthrough in Spinocerebellar Ataxia Treatment with Positive Pivotal Study Results for Troriluzole

9 months ago talkbio0Tagged Ataxia, Spinocerebellar, Neurodegenerative Disorders, New Drug Application, Submission, Troriluzole, United States Food and Drug Administration

Biohaven, Troriluzole, Spinocerebellar Ataxia (SCA), Pivotal Study Results, Neurodegenerative Disease, FDA Submission, New Drug Application (NDA)

Biohaven Revives Troriluzole Hopes with Positive Update for Spinocerebellar Ataxia

9 months ago talkbio0Tagged Ataxia, Spinocerebellar, Clinical Trials, Infrequent, Neurodegenerative Disorders, New Drug Application, SCA, Troriluzole, United States Food and Drug Administration

Troriluzole, Spinocerebellar Ataxia (SCA), Biohaven Pharmaceuticals, Neurodegenerative Disorders, FDA New Drug Application (NDA), Clinical Trials, Rare Diseases